Swan Prescription Center (Buffalo Pharmacies, Inc.), East Amherst, NY

Is Swan Prescription Center (Buffalo Pharmacies, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Swan Prescription Center (Buffalo Pharmacies, Inc.) hold a New York pharmacy license?

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions.

Has Swan Prescription Center (Buffalo Pharmacies, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Sep 16, 2019) and 1 FMD-145 letter (Sep 16, 2019) for Swan Prescription Center (Buffalo Pharmacies, Inc.). State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Buffalo Pharmacies, Inc.; Swan Prescription Center
Location
East Amherst, NY
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 16, 2019
FDA Data Dashboard inspections
1 inspection: 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Buffalo Pharmacies, Inc. dba Swan Prescription Center, a 503A facility, with 2 dated actions.

Document
Sep 16, 2019State referral letterState Referral Letter Issued 9/16/2019FDA copy (archived)
Sep 16, 2019FMD-145 letterFMD-145 Letter Issued 9/16/2019FDA copy (archived)

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Buffalo Pharmacies Inc, East Amherst, NY (FEI number 3010987875), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jul 26, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30109878751060028

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 20, 2017 to Jun 23, 2017: 6 observations

Firm on the cover
, 6035 Transit Rd . Buff alo Pha rmaci es, Inc
FEI number
3010987875
Establishment type on the cover
Produc er o f S teril e & N on-St erile Dru g Prod uct East Amhers t, N Y 1 4051 - 1803
FDA district office on the cover
1 58- 15 Liberty A venue Jamaica, NY 11 433
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Clothing of personnel engaged in the processing of drug products is no t appropriate for the duties the y perform.

Specifically, your firm failed to establish a gowning procedure and aseptic processed that reduces the possibility of chemical and microbial contamination of compounded products manufactured in the ISO 5 laminar flow hood. (a) On 6/20/17, we observed the compounding technician re-use a gowning jacket between multiple product compound preparations. As per the technician, your firm uses only one gown jacket during the daily routine compounding processes and disposes of it at the end of the day. (b) On 6/20/17, we observed the compounding technician donning gloves inside the ISO 5 laminar flow hood, exposing the product contact surface areas to exposed skin. (c) On 6/20/17, we observed the compounding technician introducing unfiltered air into a sterile bottle of Tacrolimus vet product through a syringe in order to create positive pressure.

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically, you have not performed media fills that closely simulate aseptic production operations i ncorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic o perations.

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, (a) Cleaning wipes used in the ISO 5 aseptic processing area are not sterile. Your firm is currently usi ng the non-sterile wipes, <Redac ted B4> for the sanitization of the ISO 5 laminar flow hood surface areas. (b) Sporicidal agents are not used in your facility's cleanroom and ISO 5 area. Currently, your firm use s non-sterile, <Re dac ted B4> for the disinfection of the ISO 5 laminar flow hood surface areas.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, (a) You do not conduct viable and non-viable monitoring of the ISO 5 and ISO 7 areas during dynamic processes. You do not possess the necessary equipment to conduct such testing, nor is it performed b y an outside contractor. Currently, your firm only performs non-viable monitoring of the ISO 5 and IS O 7 areas during <Redacted B4> conditions , <Redacted B4> (b) You do not perform smoke studies under dynamic conditions to demonstrate and assure proper air flow patterns in the ISO 5 laminar flow hood area.

Observation 5

Adequate ventilation is not provided.

Specifically, (a) Youor firm failed to provide adequate positive air pressure and air changes of the ISO 8 anteroom i n connection to the hallways; thus, allowing the possibility of environmental contaminants to enter t he ISO 8 are a, as per the Cleanroom Certification Report from February 16, 2017. This is an ongoing iss ue, for which your firm doesn't monitor the pressure differentials and the air changes on a routine basis.

(b) Your firm failed to provide adequate negative pressure and air changes of the ISO 8 capsule room in connection to the hallways; thus, allowing the possibility of powder product to leave the ISO 8 area, as per the Cleanroom Certification Report from February 16, 2017. This is an ongoing issue, for whic h your firm doesn't monitor the pressure differentials and the air changes on a routine basis.

Observation 6

Routine calibration and inspection of mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, (a)You have not calibrated or maintained the <Redacted B4> Incubator, <Redacted B4> <Redacted B4> since the purchase of the equipment. This equipment is used for the incubation of <Redaction B4> <Redaction B4> after <Redaction B4> monitoring of the ISO 7 cleanroom.

(b) You have not calibrated the <Redacte d B4> Model <Redacted B4> originally calibrat ed March 2013, since the purchase of this equipment. This equipment is used to test t he <Redac ted B4> of your sterilizing <Redacted B4> us ed in the processing of compounded sterile drug products.

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.